Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
